CVS Caremark Corporation: Q2 2008 10-Q Summary
Business Context and Reporting Period
This filing covers the quarterly period ended June 28, 2008. CVS Caremark Corporation operates as a fully integrated pharmacy services company with two primary segments: Retail Pharmacy (6,308 stores and MinuteClinics) and Pharmacy Services (PBM, mail order, and specialty pharmacy). The results reflect the full impact of the March 2007 merger with Caremark Rx, Inc.
Key Financial Metrics
| Metric (26 Weeks Ended) | June 28, 2008 | June 30, 2007 |
|---|---|---|
| Net Revenues | $42,466.3 million | $33,891.9 million |
| Gross Profit | $8,666.2 million | $7,461.7 million |
| Operating Profit | $2,848.2 million | $2,046.3 million |
| Net Earnings | $1,523.3 million | $1,132.5 million |
| Diluted EPS (Net Earnings) | $1.04 | $0.91 |
| Operating Cash Flow | $1,392.1 million | $1,427.2 million |
| Cash & Equivalents | $615.7 million | $1,056.6 million (Dec 29, 2007) |
| Total Debt (Short + Long Term) | $9,375.6 million | $10,481.9 million (Dec 29, 2007) |
Material Changes vs. Prior Period
- Revenue Growth: Net revenues increased by $8.6 billion (25.3%) year-over-year. The 26-week period benefited from 182 days of Caremark operations compared to 101 days in the prior year, driving a $7.9 billion increase in Pharmacy Services revenue.
- Profitability: Earnings from continuing operations rose 38.8% to $1.572 billion. Gross profit margins improved in the Retail Pharmacy segment (29.8% vs 28.5%) due to higher generic drug utilization and purchasing synergies from the Caremark merger.
- Discontinued Operations: A loss of $48.7 million (net of tax) was recorded due to lease guarantees for former subsidiaries, specifically Linens 'n Things, which filed for Chapter 11 bankruptcy in May 2008.
- Interest Expense: Net interest expense increased to $245.6 million (from $169.8 million) due to higher average debt balances used to fund the Caremark merger special dividend and share repurchase programs.
Guidance, Outlook, and Risks
- Dividend Increase: The Board authorized a 15% increase in the quarterly dividend to $0.069 per share, effective August 1, 2008.
- Share Repurchases: A new $2.0 billion share repurchase program was authorized in May 2008. The company repurchased 0.6 million shares for $23.0 million in Q2.
- Store Development: The company plans to open 120–130 new or relocated retail pharmacy stores for the remainder of 2008.
- Legal & Regulatory Risks:
- Linens 'n Things: Ongoing exposure to lease guarantees; costs are estimated but subject to change.
- Government Investigations: Ongoing cooperation with the OIG regarding Medicaid claims processing and a Rhode Island investigation into business relationships (employees acquitted in May 2008).
- Antitrust Litigation: Pending multidistrict litigation regarding pharmacy benefit manager networks.
- Market Risks: Pressure from third-party payors to reduce reimbursement rates, particularly for generic drugs, and potential changes in Medicaid reimbursement formulas (delayed until 2009 by the MIPP Act).
Investor Verification Checklist
- Merger Synergies: Verify the realization of purchasing synergies and integration cost savings in the Pharmacy Services segment.
- Generic Drug Trends: Monitor the impact of increasing generic dispensing rates (64.5% in Q2) on revenue volume versus gross profit margins.
- Discontinued Operations: Track the final settlement amount for the Linens 'n Things lease guarantees.
- Debt Management: Review the company's ability to service debt given the increased interest expense and the reduction in cash reserves from $1.06 billion to $615.7 million.
- Regulatory Environment: Assess the potential financial impact of the delayed Medicaid reimbursement formula changes and ongoing government investigations.